Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | DRD3 | P35462 | 4/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188346 | 0.83 | CYP2C9 (0.36) | DRD2PTGDRPTGDR2DRD4HTR1A | |
| SCHEMBL15006654 | 0.79 | DRD2 (0.31) | DRD2DRD3TBXA2RPTGDRPTGDR2 | |
| SCHEMBL15428829 | 0.79 | PTGDR2 (0.42) | DRD2DRD3TBXA2RPTGDRPTGDR2 | |
| SCHEMBL252924 | 0.79 | CMA1 (0.32) | — | |
| SCHEMBL12002747 | 0.76 | PSIP1 (0.31) | DRD2DRD3DRD4 | |
| SCHEMBL2189400 | 0.74 | RB1 (0.36) | DRD2DRD3PTGDRPTGDR2DRD4 | |
| SCHEMBL15436289 | 0.73 | — | — | |
| SCHEMBL15436285 | 0.73 | PSIP1 (0.31) | — | |
| SCHEMBL2188342 | 0.71 | PTGDR2 (0.41) | TBXA2RPTGDRPTGDR2 | |
| SCHEMBL2187304 | 0.71 | PTGDR2 (0.40) | DRD2DRD3TBXA2RPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | DRD2 93/4885DRD3 254/4885TBXA2R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.